[Skip to Content]
[Skip to Content Landing]
November 11, 1992

Incorrect Statement.

JAMA. 1992;268(18):2518. doi:10.1001/jama.1992.03490180050025

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


—In the Board of Trustees Report entitled "Requirements or Incentives by Government for the Use of Long-Acting Contraceptives," published in the April 1,1992, issue of THE JOURNAL (1992;267:1818-1821), on page 1818 in the fourth paragraph, the third sentence should be two sentences and read as follows: "Nevertheless, because of the potential risks of supplemental hormonal therapy Norplant is contraindicated for patients with thrombotic disease, acute liver dysfunction, or breast cancer [not "diabetes, hypertension, cardiovascular disease, thrombotic disease, acute liver dysfunction, or breast cancer"]. Patients with diabetes, hypertension, or cardiovascular disease should be monitored for adverse effects."